GlucoSentient, Inc. is a biotechnology startup founded in 2011 with a focus on transforming the traditional Blood Glucose Meter (BGM) into a device capable of detecting non-glucose targets. The company has received a $900.00K grant investment from the National Science Foundation on 16 September 2013.
Their innovative technology, based on a patent pending process, enables the BGM to quantitatively and conveniently detect various non-glucose targets such as heavy metal ions for environmental monitoring, small molecules for drug monitoring, protein markers for immunoassay diagnostics, and nucleic acids for molecular diagnostics.
GlucoSentient's approach leverages the widespread availability and proven track record of BGMs, opening new avenues for medical and environmental applications. The company operates in the biotechnology and health care industries.
By tapping into the potential of existing BGM infrastructure and expanding its capabilities, GlucoSentient positions itself as an innovative force in medical technology, offering a promising venture for investment.
